Author of

• 18973

  +

  P2.01 - Advanced NSCLC (ID 618)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)

  • 23158

    +

    P2.01-035 - Phase II Study: Weekly Docetaxel as First Line Chemotherapy for Elderly Patients with Squamous-Cell Non-Small-Cell Lung Cancer (ID 9329)

    09:00 - 09:00  |  Author(s): J.J. Shim
    • Abstract

    Background:
    Docetaxel monotherapy is one of the standard treatments for non-small-cell lung cancer in elderly patients. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. There is increasing interest in Docetaxel weekly schedule to reduce its toxicity. In this phase II clinical study, we investigate the efficacy and safety of a weekly schedule of docetaxel monotherapy in a first-line chemotherapy for advanced squamous-cell non-small-cell lung cancer in elderly patients.
    
    Method:
    Patients with stage IIIb, or stage IV squamous-cell non-small-cell lung cancer aged 65 years or older who had not previously received cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m2 days 1, 8, and 15, every 4 weeks. The primary endpoint of this study was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profile.
    
    Result:
    The patient characteristics are showed in table below. Among 12 eligible patients, the ORR was 0%, (5 patients were confirmed with stable disease, 7 patients were progressive disease. Median OS and PFS were each days and days. There were 3 adverse event of grade 3/4 (2 were dizziness and 1 was diarrhea). Neutropenia was reported on only 1 patients and was grade 1.

    Patient Characteristics

    Age (years)	78.16 ± 4.72
    Sex (male / female)	18 / 1
    Stage
    IIIB (%)	6 (31.58)
    IV (%)	13 (68.42)
    Performance Status
    0-1 (%)	15 (78.95)
    2 (%)	4 (21.05)
    Smoking
    Never (%)	1 (5.26)
    Former (%)	13 (68.42)
    Current (%)	5 (26.32)
    Amounts (pack years)	49.05 ± 28.22
    FEV1 (mL)	1.53 ± 0.53

    
    
    Conclusion:
    Our data failed to demonstrate the efficacy of docetaxel weekly regimen. Because our patients were mostly elderly and of poor general conditions, our result might show poor overall response rate. However, the incidence of side effects include neutropenia was lower than docetaxel 3-week regimen as previous reported. Further larger studies are need to confirm the efficacy and safety of docetaxel weekly regimen.